{"id":382046,"date":"2020-11-16T12:08:22","date_gmt":"2020-11-16T17:08:22","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=382046"},"modified":"2020-11-16T12:08:22","modified_gmt":"2020-11-16T17:08:22","slug":"ngm-to-host-virtual-rd-day-on-december-9-2020","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ngm-to-host-virtual-rd-day-on-december-9-2020\/","title":{"rendered":"NGM to Host Virtual R&D Day on December 9, 2020"},"content":{"rendered":"
\n

\n \u2013 Event to <\/em>
\n showcase <\/em>
\n NGM\u2019s multi-therapeutic area p<\/em>
\n ipeline<\/em>
\n ,<\/em>
\n including its oncology<\/em>
\n por<\/em>
\n tfolio<\/em>
\n and Geographic Atrophy and NASH programs <\/em>
\n \u2013<\/em>\u00a0<\/p>\n

\n \u2013<\/em>
\n Planned presentations <\/em>
\n from<\/em>
\n NGM<\/em>
\n management<\/em>
\n , <\/em>
\n NGM <\/em>
\n scientists<\/em>
\n and<\/em>
\n l<\/em>
\n eading <\/em>
\n i<\/em>
\n ndustry <\/em>
\n p<\/em>
\n hysicians<\/em>
\n \u2013<\/em>\n <\/p>\n

\n \u2013 F<\/em>
\n ireside <\/em>
\n c<\/em>
\n hat with <\/em>
\n executives from<\/em>
\n Merck Research Laboratories<\/em>
\n \u2013<\/em>\n <\/p>\n

SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) — \u00a0NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced it will host a virtual R&D Day on December 9, 2020 at 12:00 pm ET.<\/p>\n

The R&D Day will highlight NGM\u2019s productive, 100+ researcher-led discovery engine and feature NGM\u2019s pipeline of drug candidates in liver and metabolic diseases (aldafermin and MK-3655), retinal disease (NGM621) and cancer (NGM120 and NGM707). NGM also plans to unveil an additional oncology candidate at the event.<\/p>\n

Members of NGM\u2019s management and senior NGM scientists will present the company\u2019s pipeline of programs and the unmet patient needs each aims to address. Guest speakers will include:<\/p>\n